Nothing Special   »   [go: up one dir, main page]

CA2519584A1 - Utilisation de pramipexol pour reduire l'absorption excessive d'aliments chez les enfants - Google Patents

Utilisation de pramipexol pour reduire l'absorption excessive d'aliments chez les enfants Download PDF

Info

Publication number
CA2519584A1
CA2519584A1 CA002519584A CA2519584A CA2519584A1 CA 2519584 A1 CA2519584 A1 CA 2519584A1 CA 002519584 A CA002519584 A CA 002519584A CA 2519584 A CA2519584 A CA 2519584A CA 2519584 A1 CA2519584 A1 CA 2519584A1
Authority
CA
Canada
Prior art keywords
pramipexol
children
optionally
use according
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002519584A
Other languages
English (en)
Inventor
Joachim Mierau
Juergen Reess
Marion Wienrich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2519584A1 publication Critical patent/CA2519584A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/428Thiazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002519584A 2003-03-21 2004-03-18 Utilisation de pramipexol pour reduire l'absorption excessive d'aliments chez les enfants Abandoned CA2519584A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10312809.3 2003-03-21
DE10312809A DE10312809A1 (de) 2003-03-21 2003-03-21 Pramipexol zur Reduzierung übermäßiger Nahrungsaufnahme bei Kindern
PCT/EP2004/002793 WO2004082680A1 (fr) 2003-03-21 2004-03-18 Utilisation de pramipexol pour reduire l'absorption excessive d'aliments chez les enfants

Publications (1)

Publication Number Publication Date
CA2519584A1 true CA2519584A1 (fr) 2004-09-30

Family

ID=32921094

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002519584A Abandoned CA2519584A1 (fr) 2003-03-21 2004-03-18 Utilisation de pramipexol pour reduire l'absorption excessive d'aliments chez les enfants

Country Status (5)

Country Link
EP (1) EP1608367A1 (fr)
JP (1) JP2006520764A (fr)
CA (1) CA2519584A1 (fr)
DE (1) DE10312809A1 (fr)
WO (1) WO2004082680A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016046150A1 (fr) * 2014-09-25 2016-03-31 Boehringer Ingelheim Vetmedica Gmbh Polythérapie avec des inhibiteurs de sglt2 et des agonistes de la dopamine utilisée pour la prévention des troubles métaboliques chez des équidés
US10220017B2 (en) 2015-08-27 2019-03-05 Boehringer Ingelheim Vetmedica Gmbh Liquid pharmaceutical compositions comprising SGLT-2 inhibitors
US10603300B2 (en) 2014-01-23 2020-03-31 Boehringer Ingelheim Vetmedica Gmbh Treatment of metabolic disorders in canine animals
US10617666B2 (en) 2013-12-17 2020-04-14 Boehringer Ingelheim Vetmedica Gmbh Treatment of metabolic disorders in feline animals
US10688116B2 (en) 2014-04-01 2020-06-23 Boehringer Ingelheim Vetmedica Gmbh Treatment of metabolic disorders in equine animals
US10864225B2 (en) 2013-04-04 2020-12-15 Boehringer Ingelheim Vetmedica Gmbh Treatment of metabolic disorders in equine animals

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100168191A1 (en) * 2007-05-25 2010-07-01 Boehringer Ingelheim International Gmbh Pharmaceutical formulation comprising pramipexole

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8800823A (nl) * 1987-04-10 1988-11-01 Sandoz Ag Werkwijze voor het toepassen van dopamine-receptor agonisten en farmaceutische preparaten die deze agonisten bevatten.
US20010016582A1 (en) * 1997-04-28 2001-08-23 Anthony H. Cincotta Method and composition for the treatment of lipid and glucose metabolism disorders
WO2001041763A1 (fr) * 1999-12-10 2001-06-14 University Of Cincinnati Traitement des troubles de l'accoutumance
DE10148233A1 (de) * 2001-09-28 2003-04-10 Boehringer Ingelheim Pharma Verbindungen zur Reduzierung übermäßiger Nahrungsaufnahme
US20040077679A1 (en) * 2002-07-29 2004-04-22 Cincotta Anthony H. Therapeutic treatment for the metabolic syndrome and type 2 diabetes

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10864225B2 (en) 2013-04-04 2020-12-15 Boehringer Ingelheim Vetmedica Gmbh Treatment of metabolic disorders in equine animals
US10617666B2 (en) 2013-12-17 2020-04-14 Boehringer Ingelheim Vetmedica Gmbh Treatment of metabolic disorders in feline animals
US11896574B2 (en) 2013-12-17 2024-02-13 Boehringer Ingelheim Vetmedica Gmbh Treatment of metabolic disorders in feline animals
US10603300B2 (en) 2014-01-23 2020-03-31 Boehringer Ingelheim Vetmedica Gmbh Treatment of metabolic disorders in canine animals
US11433045B2 (en) 2014-01-23 2022-09-06 Boehringer Ingelheim Vetmedica Gmbh Treatment of metabolic disorders in canine animals
US10688116B2 (en) 2014-04-01 2020-06-23 Boehringer Ingelheim Vetmedica Gmbh Treatment of metabolic disorders in equine animals
WO2016046150A1 (fr) * 2014-09-25 2016-03-31 Boehringer Ingelheim Vetmedica Gmbh Polythérapie avec des inhibiteurs de sglt2 et des agonistes de la dopamine utilisée pour la prévention des troubles métaboliques chez des équidés
US10555958B2 (en) 2014-09-25 2020-02-11 Boehringer Ingelheim Vetmedica Gmbh Combination treatment of SGLT2 inhibitors and dopamine agonists for preventing metabolic disorders in equine animals
AU2015320975B2 (en) * 2014-09-25 2020-10-08 Boehringer Ingelheim Vetmedica Gmbh Combination treatment of SGLT2 inhibitors and dopamine agonists for preventing metabolic disorders in equine animals
US10220017B2 (en) 2015-08-27 2019-03-05 Boehringer Ingelheim Vetmedica Gmbh Liquid pharmaceutical compositions comprising SGLT-2 inhibitors

Also Published As

Publication number Publication date
JP2006520764A (ja) 2006-09-14
EP1608367A1 (fr) 2005-12-28
WO2004082680A1 (fr) 2004-09-30
DE10312809A1 (de) 2004-09-30

Similar Documents

Publication Publication Date Title
US20080051444A1 (en) Compounds for the reduction of excessive food intake
JP2006516549A (ja) パーキンソン病の治療用医薬組成物及び治療方法
US4330558A (en) Pharmaceutical composition and method for treating peripheral orthostatic hypotension
CA2519584A1 (fr) Utilisation de pramipexol pour reduire l'absorption excessive d'aliments chez les enfants
JP2002538102A (ja) 光学的に純粋なr(+)オンダンセトロンを使用する無呼吸および無呼吸障害の治療方法
AU2005205880B2 (en) Compounds for the sustained reduction of body weight
JP2017078089A (ja) 過活動膀胱の治療のためのソリフェナシンと唾液分泌刺激剤の組合せ
US20040266794A1 (en) Pramipexole for the reduction of excessive food intake for children
JP2007519646A5 (fr)
US20030036548A1 (en) Method for treating anhedonia using dopamine agonists
US8202884B2 (en) Treatment of type 2 diabetes
CA2614833A1 (fr) Composition pharmaceutique utile dans le traitement des troubles de la libido
JP2014513689A (ja) 過活動膀胱の治療のためのトロスピウムと唾液分泌刺激剤の組合せ
MXPA06008205A (en) Compounds for the sustained reduction of body weight
JP2005533786A (ja) 不穏下肢症候群を治療するためのドパミン部分作用剤の使用、並びに対応する医薬製剤
Valeshabad et al. Clinical Study Attenuation of Hemodynamic Responses to Laryngoscopy and Tracheal Intubation: Propacetamol versus Lidocaine—A Randomized Clinical Trial
Valeshabad et al. Attenuation of Hemodynamic Responses to Laryngoscopy and Tracheal Intubation–Propacetamol versus Lidocaine
JP2003503452A (ja) 治療剤

Legal Events

Date Code Title Description
FZDE Dead